This page shows the latest Radius International news and features for those working in and with pharma, biotech and healthcare.
There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...